Equity Profile

ARQT

Arcutis Biotherapeutics, Inc.

Health CareBiotechnology$3.4B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of the company's profitability and will indicate how well Arcutis is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is essential to assess the demand for Arcutis's products and its market position within the biotechnology industry.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARQT Q2-2026 Earnings Preview

Context

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases. With a market cap of $3 billion, it operates in the healthcare sector, addressing significant unmet needs in dermatology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.67%

Avg Stock Reaction

+2.77%

Last Quarter Recap

In Q1 2026, Arcutis reported an EPS of -$0.09, which was a significant miss compared to the estimate of -$0.02. The stock reacted positively, gaining 3.20% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Arcutis's upcoming earnings report are mixed, given the recent earnings history and the lack of analyst estimates. Investors will be keen to see if the company can continue its trend of beating EPS estimates.

Bull Case

If Arcutis can report better-than-expected EPS and show strong revenue growth, it could significantly boost investor confidence and lead to a sharp increase in the stock price.

Bear Case

Conversely, if the company misses EPS estimates again and fails to provide guidance on revenue growth, it could lead to a sell-off as investors reassess the company's prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The market will closely watch this figure to see if Arcutis can maintain its trend of beating EPS estimates, which could influence investor sentiment.

What guidance will management provide on revenue growth?

Any insights into future revenue growth will be crucial for investors to assess the company's trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Arcutis's ability to rebound from recent misses, as historical data shows a strong EPS beat rate of 88%.

Supporting Evidence

The stock has historically reacted positively even after misses, suggesting resilience.

Options pricing indicates a significant expected move, reflecting heightened investor interest.

Key Risk

If the EPS comes in above -$0.05, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's earnings report will be pivotal in determining whether Arcutis can sustain its growth trajectory in the competitive biotechnology landscape.

Bull Confirmed If

Reporting an EPS of $0.05 or better would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS of -$0.15 or worse would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±18.36%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±18.4% while ARQT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

62.0%

Calls (13K)P/C Ratio: 0.14Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcutis beats expectations, history suggests the stock could rise by an average of 2.7%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of around 3.2%, leading to increased scrutiny of its growth prospects.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements.
2Management's commentary on competitive landscape changes.
3Insights into customer feedback on recent product launches.
4Any discussion on cost management strategies.
5Future guidance on market expansion efforts.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of the company's profitability and will indicate how well Arcutis is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is essential to assess the demand for Arcutis's products and its market position within the biotechnology industry.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARQT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.67%

Avg Stock Reaction

+2.77%

Last Quarter Recap

In Q1 2026, Arcutis reported an EPS of -$0.09, which was a significant miss compared to the estimate of -$0.02. The stock reacted positively, gaining 3.20% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Arcutis can report better-than-expected EPS and show strong revenue growth, it could significantly boost investor confidence and lead to a sharp increase in the stock price.

Bear Case

Conversely, if the company misses EPS estimates again and fails to provide guidance on revenue growth, it could lead to a sell-off as investors reassess the company's prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The market will closely watch this figure to see if Arcutis can maintain its trend of beating EPS estimates, which could influence investor sentiment.

What guidance will management provide on revenue growth?

Any insights into future revenue growth will be crucial for investors to assess the company's trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Arcutis's ability to rebound from recent misses, as historical data shows a strong EPS beat rate of 88%.

Supporting Evidence

The stock has historically reacted positively even after misses, suggesting resilience.

Options pricing indicates a significant expected move, reflecting heightened investor interest.

Key Risk

If the EPS comes in above -$0.05, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's earnings report will be pivotal in determining whether Arcutis can sustain its growth trajectory in the competitive biotechnology landscape.

Bull Confirmed If

Reporting an EPS of $0.05 or better would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS of -$0.15 or worse would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±18.36%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±18.4% while ARQT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

62.0%

Calls (13K)P/C Ratio: 0.14Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcutis beats expectations, history suggests the stock could rise by an average of 2.7%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of around 3.2%, leading to increased scrutiny of its growth prospects.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements.
2Management's commentary on competitive landscape changes.
3Insights into customer feedback on recent product launches.
4Any discussion on cost management strategies.
5Future guidance on market expansion efforts.